Beimeprost eye drops and preparation method thereof
By using polyoxyethylene hydrogenated castor oil, pH regulator and stabilizer in Bemeprost eye drops, the solubility and stability of eye drops are solved, and the efficient release and stability of the drug are achieved. Improves patient comfort and shelf life of eye drops.
Patent Information
- Application Number
- CN202411242639.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-08
AI Technical Summary
The existing Bemeprost eye drops have low solubility and are unstable in water, which can easily produce degraded impurities and affect the medicinal effect.
Polyoxyethylene hydrogenated castor oil, pH regulator, stabilizer and osmotic pressure regulator are used to improve the solubility and stability of Bemeprost, reduce the influence of external factors by forming a protective layer and buffer system, and use hydroxyl Propyl-β-cyclodextrin and antioxidants enhance the solubility and stability of the drug.
It improves the solubility and stability of Bemeprost eye drops, reduces drug degradation, enhances the effective release of drugs and patient comfort, and extends the shelf life of eye drops.
Smart Images

Figure BDA0005029740040000061
Abstract
Description
Technical Field
[0001] The present application relates to the field of medical technology, and in particular to a bimatoprost eye drop and a preparation method thereof. Background Art
[0002] Glaucoma and ocular hypertension are common ophthalmic diseases, which can lead to visual impairment or even blindness in severe cases. At present, drug treatment is one of the main means to reduce intraocular pressure and control the disease. As an effective drug for lowering intraocular pressure, bimatoprost has been widely used in clinical practice.
[0003] Existing bimatoprost eye drops are usually prepared by mixing bimatoprost with auxiliary ingredients into an aqueous solution. However, the solubility of bimatoprost in water is reduced. At the same time, the aqueous solution of bimatoprost is extremely unstable and easily produces certain degradation impurities, which further affects the medicinal effect of the eye drops. Summary of the invention
[0004] In order to improve the solubility and stability of bimatoprost eye drops, the present application provides a bimatoprost eye drops and a preparation method thereof.
[0005] In the first aspect, the present application provides a bimatoprost eye drops, which adopts the following technical solution: A bimatoprost eye drop comprises the following raw materials in parts by weight: 0.03-0.1 parts of bimatoprost, 0.03-0.08 parts of polyoxyethylene hydrogenated castor oil, 0.01-1 parts of a pH regulator, 0.3-1 parts of a stabilizer, 0.1-0.6 parts of an osmotic pressure regulator and water for injection; the stabilizer is one of polyvinyl alcohol and hydroxypropyl methylcellulose.
[0006] By adopting the above technical solution, a pH regulator is used in the raw materials of bimatoprost eye drops, so that the eye drops are close to the physiological pH value of the human eye, the stability of the drug and the comfort of the patient are improved, and the degradation problem caused by the pH value is reduced. Polyoxyethylene hydrogenated castor oil reduces the interfacial tension between water and the active components of the eye drops, which can increase the solubility of bimatoprost in water, improve the effective release of the active components of the eye drops, and promote the dissolution and dispersion of the active components of the eye drops.
[0007] Polyvinyl alcohol and hypromellose, as high molecular polymers, can form a protective layer, reduce the influence of external factors such as air and light on the active components of eye drops, and reduce the degradation of the active components of eye drops.
[0008] Preferably, the osmotic pressure regulator is at least one of sodium chloride, potassium chloride, sodium acetate, boric acid, borax, propylene glycol, mannitol, and glucose.
[0009] By adopting the above technical scheme, sodium chloride, potassium chloride, sodium acetate, boric acid, borax, propylene glycol, mannitol, and glucose are used as osmotic pressure regulators to adjust the osmotic pressure of eye drops to match the intraocular fluid, reduce the osmotic pressure shock caused by eye drops on the ocular surface, and improve the electrolyte balance of intraocular fluid. Boric acid and borax can form a buffer system to resist external acid-base changes and maintain the pH value of eye drops stable. Propylene glycol can increase the solubility of drugs and adjust the osmotic pressure of eye drops by interacting with water molecules. Mannitol can use its own high osmotic pressure characteristics to attract water, adjust the osmotic pressure of intraocular fluid, promote the discharge of water from eye tissues, and reduce edema.
[0010] Preferably, the pH adjuster is at least one of hydrochloric acid, citric acid, sodium citrate, disodium hydrogen phosphate, and sodium dihydrogen phosphate.
[0011] By adopting the above technical solution, hydrochloric acid, citric acid, sodium citrate, disodium hydrogen phosphate, and sodium dihydrogen phosphate are used as pH adjusters to react with hydrogen ions or hydroxide ions in the eye drops to resist external acid-base changes and maintain the pH value of the eye drops stable.
[0012] Preferably, the raw materials of the bimatoprost eye drops also include 0.01-0.02 parts of antibacterial agent, 0.05-0.1 parts of hydroxypropyl-β-cyclodextrin, and 0.05-0.1 parts of antioxidant.
[0013] By adopting the above technical solution, hydroxypropyl-β-cyclodextrin can form inclusion complexes with bimatoprost molecules, encapsulating the drug molecules in the hydrophobic cavity of cyclodextrin, increasing the solubility of the drug in the aqueous phase, improving the hydrophilicity of the drug molecules, and thus promoting the wetting and penetration of the drug on the cornea. Hydroxypropyl-β-cyclodextrin can also reduce the local concentration of drug molecules, reduce direct stimulation to ocular surface cells, and improve the mildness of the drug.
[0014] Preferably, the antibacterial agent is at least one of benzalkonium chloride, ethyl p-hydroxybenzoate and sorbic acid.
[0015] By adopting the above technical solution, benzalkonium chloride can destroy the cell membrane of microorganisms, promote the leakage of cell contents, and then inhibit the growth and reproduction of microorganisms, and reduce the contamination of eye drops by microorganisms during use. At the same time, benzalkonium chloride has the function of a surfactant, and can also enhance the solubility of bimatoprost, playing a solubilizing effect. Ethyl paraben and sorbic acid can interfere with the metabolic process of microorganisms, inhibit the enzyme activity of microorganisms, inhibit the growth and reproduction of microorganisms, and improve the stability and shelf life of eye drops.
[0016] Preferably, the antioxidant is at least one of vitamin C, amino acids and lecithin.
[0017] By adopting the above technical scheme, vitamin C has efficient antioxidant properties, can remove free radicals, protect eye tissue from oxidative damage, and promote the repair and regeneration of ocular surface cells. Lecithin can improve the lubricity and stability of the ocular surface, reduce dry eye symptoms, and has certain anti-inflammatory and antioxidant effects, inhibiting the production of inflammatory mediators, reducing inflammatory reactions on the ocular surface, and reducing dryness and irritation of the ocular surface. Amino acids provide ocular surface cells with substances required for structure and function by participating in protein synthesis, and at the same time, as a source of energy, promote cell metabolism and repair processes. It can be compounded with vitamin C and lecithin to promote cell repair and reduce damage to ocular tissues caused by oxidative stress.
[0018] In the second aspect, the present application provides a method for preparing bimatoprost eye drops, using the following technical solution: A method for preparing bimatoprost eye drops, comprising the following specific steps: Dissolve polyoxyethylene hydrogenated castor oil in water for injection, add bimatoprost and mix, heat and stir to dissolve, then add pH adjuster, stabilizer and osmotic pressure regulator and mix evenly, cool to room temperature, dilute to the prepared volume with water for injection, filter and obtain bimatoprost eye drops.
[0019] By adopting the above technical scheme, the prepared bimatoprost eye drops have good solubility and stability, the preparation method is simple and easy, and is suitable for large-scale production.
[0020] Preferably, the filtration is performed using a filter membrane with a size of 0.2-0.4 μm.
[0021] By adopting the above technical solution and filtering the eye drops with a filter membrane of a suitable size, insoluble particles can be removed and the clarity and safety of the eye drops can be maintained.
[0022] In summary, this application has the following beneficial effects: 1. Since the present application uses pH regulator, polyoxyethylene hydrogenated castor oil, stabilizer and active component of Bemeprostil in the raw materials of Bemeprostil eye drops, the solubility of Bemeprostil in water is improved, and the stability of the drug and the comfort of patients are improved. Using polyvinyl alcohol and hydroxypropyl methylcellulose as stabilizers can reduce the influence of external factors on the active components of eye drops and reduce the oxidation and hydrolysis of eye drops.
[0023] 2. Hydroxypropyl-β-cyclodextrin is used in this application to enhance the solubility of the drug in the aqueous phase, improve the hydrophilicity of the drug molecules, promote the wetting and penetration of the active components of the eye drops on the cornea, and improve the mildness of the drug. Benzalkonium chloride, ethyl paraben, and sorbic acid are used to inhibit the growth and reproduction of microorganisms and reduce the phenomenon of microbial contamination of eye drops during use. At the same time, the solubility of bimatoprost can also be enhanced to achieve a solubilization effect. DETAILED DESCRIPTION
[0024] The present application is further described in detail below with reference to the embodiments.
[0025] All raw materials in the examples are commercially available. Example
[0026] Example 1 The present embodiment provides a bimatoprost eye drop, comprising the following raw materials in parts by weight: 0.08 g of bimatoprost, 0.05 g of polyoxyethylene hydrogenated castor oil, 0.5 g of pH regulator, 0.8 g of stabilizer, 0.3 g of osmotic pressure regulator and water for injection, wherein the polyoxyethylene hydrogenated castor oil is polyoxyethylene 40 hydrogenated castor oil, the pH regulator is disodium hydrogen phosphate and sodium dihydrogen phosphate, the osmotic pressure regulator is boric acid and borax, the mass ratio of boric acid to borax is 10:1, the stabilizer is polyvinyl alcohol, and the molecular weight of polyvinyl alcohol is 25,000.
[0027] The preparation method of bimatoprost eye drops comprises the following specific steps: Dissolve polyoxyethylene hydrogenated castor oil in water for injection, add bimatoprost and mix, stir and dissolve at 40°C to form a bimatoprost mixed solution; then dissolve the pH adjuster, stabilizer and osmotic pressure regulator in boiling water for injection, mix evenly, stir and dissolve, add to the bimatoprost mixed solution after cooling to room temperature, adjust the pH to neutral, dilute with water for injection to prepare 2500 ml, filter through a 0.3 μm filter membrane, and aseptically fill to prepare 1000 bottles of bimatoprost eye drops.
[0028] Example 2 The difference between Example 2 and Example 1 is that the amount of bimatoprost used in the raw materials of bimatoprost eye drops is 0.03g, the amount of polyoxyethylene hydrogenated castor oil used is 0.03g, the amount of pH adjuster used is 0.01g, the amount of stabilizer used is 0.3g, and the amount of osmotic pressure regulator used is 0.1g.
[0029] Example 3 The difference between Example 3 and Example 1 is that the amount of bimatoprost used in the raw materials of bimatoprost eye drops is 0.1g, the amount of polyoxyethylene hydrogenated castor oil used is 0.08g, the amount of pH adjuster used is 1g, the amount of stabilizer used is 1g, and the amount of osmotic pressure regulator used is 0.6g.
[0030] Example 4 The difference between Example 4 and Example 1 is that the osmotic pressure regulator in the raw material of bimatoprost eye drops is sodium chloride.
[0031] Example 5 The difference between Example 5 and Example 1 is that the raw materials of Bimatoprost eye drops also include 0.015g of antibacterial agent and 0.08g of antioxidant, wherein the antibacterial agent is benzalkonium chloride and the antioxidant is vitamin C.
[0032] The preparation method of bimatoprost eye drops comprises the following specific steps: Dissolve polyoxyethylene hydrogenated castor oil in water for injection, add bimatoprost and mix, stir and dissolve at 40°C to form a bimatoprost mixed solution; then dissolve the pH adjuster, stabilizer, osmotic pressure regulator, antibacterial agent, and antioxidant in boiling water for injection, mix evenly, stir and dissolve, cool to room temperature and add to the bimatoprost mixed solution, adjust the pH to neutral, dilute with water for injection to prepare 2500 ml, filter through a 0.3 μm filter membrane, and aseptically fill to prepare 1000 bottles of bimatoprost eye drops.
[0033] Example 6 The difference between Example 6 and Example 5 is that the antibacterial agent in the raw material of bimatoprost eye drops is a mixture of ethyl p-hydroxybenzoate and sorbic acid, and the mass ratio of ethyl p-hydroxybenzoate to sorbic acid is 1:1.
[0034] Example 7 The difference between Example 7 and Example 5 is that the antioxidant in the raw materials of bimatoprost eye drops is a mixture of vitamin C, amino acids and lecithin, and the mass ratio of vitamin C, amino acids and lecithin is 1:1:1.
[0035] Example 8 The difference between Example 8 and Example 5 is that the raw materials of the bimatoprost eye drops also include 0.08 g of hydroxypropyl-β-cyclodextrin.
[0036] The preparation method of bimatoprost eye drops comprises the following specific steps: Dissolve polyoxyethylene hydrogenated castor oil in water for injection, add hydroxypropyl-β-cyclodextrin and bimatoprost, mix, and stir to dissolve at 40°C to form a bimatoprost mixed solution; then dissolve the pH adjuster, stabilizer, osmotic pressure regulator, antibacterial agent, and antioxidant in boiling water for injection, mix evenly, stir to dissolve, cool to room temperature, and add to the bimatoprost mixed solution, adjust the pH to neutral, dilute with water for injection to prepare 2500 ml, filter through a 0.3 μm filter membrane, and aseptically fill to prepare 1000 bottles of bimatoprost eye drops.
[0037] Example 9 The difference between Example 9 and Example 8 is that the amount of the antibacterial agent used in the raw materials of bimatoprost eye drops is 0.01 g, the amount of the antioxidant used is 0.1 g, and the amount of hydroxypropyl-β-cyclodextrin used is 0.05 g.
[0038] Example 10 The difference between Example 10 and Example 8 is that the amount of the antibacterial agent used in the raw materials of bimatoprost eye drops is 0.02 g, the amount of the antioxidant used is 0.05 g, and the amount of hydroxypropyl-β-cyclodextrin used is 0.1 g.
[0039] Comparative Example Comparative Example 1 The difference between Comparative Example 1 and Example 1 is that polyoxyethylene hydrogenated castor oil is not used in the raw materials of bimatoprost eye drops.
[0040] The preparation method of bimatoprost eye drops comprises the following specific steps: Mix bimatoprost and water for injection in a mass ratio of 1:1, and stir at 40°C for 30 minutes to form a bimatoprost solution; then dissolve the pH adjuster, stabilizer, and osmotic pressure regulator in boiling water for injection, mix evenly, stir to dissolve, cool to room temperature and add to the bimatoprost solution, adjust the pH to neutral, dilute with water for injection to prepare 2500 ml, filter through a 0.3 μm filter membrane, and aseptically fill to prepare 1000 bottles of bimatoprost eye drops.
[0041] Comparative Example 2 The difference between Comparative Example 2 and Example 1 is that polyoxyethylene hydrogenated castor oil and stabilizer are not used in the raw materials of bimatoprost eye drops.
[0042] The preparation method of bimatoprost eye drops comprises the following specific steps: Mix bimatoprost and water for injection in a mass ratio of 1:1, and stir at 40°C for 30 minutes to form a bimatoprost solution; then dissolve the pH adjuster and osmotic pressure regulator in boiling water for injection, mix evenly, stir to dissolve, cool to room temperature and add to the bimatoprost solution, adjust the pH to neutral, dilute with water for injection to prepare 2500 ml, filter through a 0.3μm filter membrane, and aseptically fill to prepare 1000 bottles of bimatoprost eye drops.
[0043] Performance testing The following performance tests were performed on the bimatoprost eye drops provided in Examples 1-10 and Comparative Examples 1-2 of the present application, and the specific test results are shown in Table 1.
[0044] Detection Methods 1. Determination of the content of the main drug According to the high performance liquid chromatography method (Appendix VD of Part II of the Chinese Pharmacopoeia 2000 Edition), weigh about 60 mg of the bimatoprost reference substance, dissolve it in a diluent [a mixed solution of water-acetonitrile-methanol (78:22:10)] and dilute it to a solution with a concentration of 0.06 mg / ml as the reference solution; measure 5 ml of the bimatoprost eye drops prepared in this application, place it in a 25 ml volumetric flask, add the diluent to the scale, shake well, and use it as the test sample solution; accurately measure 100 ul of the reference substance solution and the test sample solution, inject them into the liquid chromatograph, record the chromatogram, and calculate the peak area according to the external standard method.
[0045] 2. Quality Inspection With reference to the standards of eye drops in Appendix II of the 2005 edition of the Chinese Pharmacopoeia, the bimatoprost eye drops prepared in this application were inspected for content of relevant substances, visible foreign matter, and appearance.
[0046] Table 1: Performance test results data table It can be seen from the performance test results that the bemiprost eye drops prepared in the present application have good stability and solubility, and the impurity content is low. The present application embodiment uses polyoxyethylene hydrogenated castor oil, a stabilizer and other components in combination to promote the dissolution and dispersion of the active components of the eye drops. Using polyvinyl alcohol and hypromellose as stabilizers can form a protective layer in the eye drop system to reduce the degradation of the active components of the eye drops.
[0047] By comparing Examples 5-7 with Example 1, it can be seen that by adding different types of antibacterial agents and antioxidants to the raw materials of Bimatoprost eye drops, it can be seen from the performance test results that the concentration of the main drug content of Bimatoprost eye drops is increased, which reduces the degradation of the main drug components of Bimatoprost eye drops.
[0048] By comparing Examples 8-10 with Example 1, it can be seen that by adding hydroxypropyl-β-cyclodextrin to the raw materials of bimatoprost eye drops, it can be seen from the performance test results that the stability of bimatoprost eye drops is further improved. At the same time, the bimatoprost eye drops prepared in the present application have higher stability and solubility.
[0049] By comparing Comparative Examples 1-2 with Example 1, it can be seen that Comparative Example 1 does not use polyoxyethylene hydrogenated castor oil, and Comparative Example 2 does not use polyoxyethylene hydrogenated castor oil and stabilizer. From the performance test results, it can be seen that the solubility of the prepared bimatoprost eye drops is reduced and the appearance color changes.
[0050] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.
Claims
1. A bimatoprost eye drops, characterized in that: The invention comprises the following raw materials in parts by weight: 0.03-0.1 parts of bimatoprost, 0.03-0.08 parts of polyoxyethylene hydrogenated castor oil, 0.01-1 parts of pH regulator, 0.3-1 parts of stabilizer, 0.1-0.6 parts of osmotic pressure regulator and water for injection; the stabilizer is one of polyvinyl alcohol and hydroxypropyl methylcellulose.
2. The bimatoprost eye drops according to claim 1, characterized in that The osmotic pressure regulator is at least one of sodium chloride, potassium chloride, sodium acetate, boric acid, borax, propylene glycol, mannitol, and glucose.
3. The bimatoprost eye drops according to claim 1, characterized in that The pH adjuster is at least one of hydrochloric acid, citric acid, sodium citrate, disodium hydrogen phosphate, and sodium dihydrogen phosphate.
4. The bimatoprost eye drops according to claim 1, characterized in that The raw materials of the bimatoprost eye drops also include 0.01-0.02 parts of antibacterial agent, 0.05-0.1 parts of hydroxypropyl-β-cyclodextrin, and 0.05-0.1 parts of antioxidant.
5. The bimatoprost eye drops according to claim 4, characterized in that The antibacterial agent is at least one of benzalkonium chloride, ethyl p-hydroxybenzoate and sorbic acid.
6. The bimatoprost eye drops according to claim 4, characterized in that The antioxidant is at least one of vitamin C, amino acid and lecithin.
7. A method for preparing the bimatoprost eye drops according to any one of claims 1 to 6, characterized in that: The specific steps include: Dissolve polyoxyethylene hydrogenated castor oil in water for injection, add bimatoprost and mix, heat and stir to dissolve, then add pH adjuster, stabilizer and osmotic pressure regulator and mix evenly, cool to room temperature, dilute to the prepared volume with water for injection, filter and obtain bimatoprost eye drops.
8. The method for preparing bimatoprost eye drops according to claim 7, characterized in that: The filtration is performed using a filter membrane with a size of 0.2-0.4 μm.
Citation Information
Cited By
A fluproquilon ophthalmic formulation and a method of preparing the same
CN122911893A
